首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth facto
【24h】

Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth facto

机译:广谱和选择性丝氨酸蛋白酶抑制剂可预防蛛网膜下腔出血后血小板衍生的生长因子-BB的表达和脑血管痉挛:重组体血小板衍生生长液的脑池注入引起的血管痉挛

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Plasma serine protease cascade, including the complement system and thrombin, is activated in the subarachnoid space during the acute phase after subarachnoid hemorrhage (SAH). To examine the effect of protease cascade-based inflammation and subsequent vascular repair in the development of cerebral vasospasm, we examined the effect of 2 synthetic serine protease inhibitors-FUT-175, an inhibitor of thrombin and the complement system, and argatroban, a selective inhibitor of thrombin-on the development of cerebral vasospasm in a rabbit SAH model. METHODS: One hundred Japanese White male rabbits were used in the study. The SAH was simulated by a single injection of autologous arterial blood into the cisterna magna. To evaluate the development of cerebral vasospasm, the caliber of the basilar artery was measured on x-ray film before and at 2 days after SAH. Nine groups of rabbits (n=6 each) were treated with continuous intravenous injection of FUT-175 (2.5, 5, 10, or 20 mg/d), argatroban (1.25, 2.5, or 5 mg/d), or the same amount of saline (vehicle) for 48 hours, starting 40 minutes after SAH. Two days after SAH, the expression of homodimer of platelet-derived growth factor-BB (PDGF-BB) in the basilar artery was examined with immunohistochemical techniques. In 20 normal rabbits, 5 microg of recombinant PDGF-BB or vehicle was injected into the cisterna magna, and the basilar arteries were examined on angiograms for 48 hours. RESULTS: Significant differences were observed in the caliber of the basilar arteries between the vehicle group and the groups with the 3 larger doses of FUT-175 (vehicle, 52+/-5.0%; 5 mg, 79+/-5.7%; 10 mg, 80+/-2.5%; 20 mg, 80+/-3.7%) and between the vehicle group and the groups with the 2 larger doses of argatroban (vehicle, 52+/-6.4%; 2.5 mg, 81+/-9.0%; 5 mg, 85+/-4.1%) (P<0.05). In the histological examination, administration of effective doses of FUT-175 or argatroban suppressed the expression of PDGF-BB in the endothelial and medial smooth muscle cell layers. Exogenous PDGF-BB caused delayed and prolonged vasoconstriction on normal basilar arteries. CONCLUSIONS: Activation of the serine protease cascade and/or thrombin after SAH was demonstrated to play an essential role in the development of cerebral vasospasm. The expression of PDGF-BB-like protein in the arterial walls correlated with the development of cerebral vasospasm. Elevated PDGF-BB level in the subarachnoid space was found to induce delayed and chronic vasoconstriction.
机译:背景与目的:蛛网膜下腔出血(SAH)后的急性期,血浆丝氨酸蛋白酶级联反应(包括补体系统和凝血酶)在蛛网膜下腔被激活。为了检查蛋白酶级联炎症和随后的血管修复在脑血管痉挛发展中的作用,我们检查了两种合成的丝氨酸蛋白酶抑制剂-FUT-175(一种凝血酶和补体系统的抑制剂)和argatroban(一种选择性的抑制剂)的作用。凝血酶抑制剂对兔SAH模型脑血管痉挛的发展方法:使用一百只日本白公兔进行研究。通过将自体动脉血单次注入大水罐来模拟SAH。为了评估脑血管痉挛的发展,在SAH之前和之后2天在X射线胶片上测量了基底动脉的口径。连续静脉注射FUT-175(2.5、5、10或20 mg / d),argatroban(1.25、2.5或5 mg / d)或相同剂量的9组兔子(每组n = 6)在SAH后40分钟开始48小时内加入适量的盐水(车辆)。 SAH后两天,用免疫组织化学技术检查基底动脉中血小板衍生的生长因子-BB(PDGF-BB)同型二聚体的表达。在20只正常的兔子中,将5微克的重组PDGF-BB或媒介物注射入大水罐中,并在血管造影照片上检查基底动脉48小时。结果:在媒介物组与使用3种较大剂量的FUT-175(媒介物,52 +/- 5.0%; 5 mg,79 +/- 5.7%; 10)之间的基底动脉口径之间存在显着差异。毫克,80 +/- 2.5%; 20毫克,80 +/- 3.7%),以及在媒介物组与含2剂更大剂量阿加曲班的组之间(媒介物,52 +/- 6.4%; 2.5毫克,81 + / -9.0%; 5 mg,85 +/- 4.1%(P <0.05)。在组织学检查中,给予有效剂量的FUT-175或阿加曲班可抑制PDGF-BB在内皮和内侧平滑肌细胞层中的表达。外源性PDGF-BB导致正常基底动脉的血管收缩延迟和延长。结论:SAH后丝氨酸蛋白酶级联和/或凝血酶的活化被证明在脑血管痉挛的发展中起重要作用。 PDGF-BB样蛋白在动脉壁的表达与脑血管痉挛的发展有关。发现蛛网膜下腔中PDGF-BB水平升高可诱发延迟性和慢性血管收缩。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号